LENZ Therapeutics (LENZ) Other Non-Current Liabilities (2020 - 2024)
LENZ Therapeutics (LENZ) reported Other Non-Current Liabilities of $111000.0 for Q1 2024, down 87.26% year-over-year from $871000.0 in Q2 2023, and down 87.26% on a QoQ basis from $871000.0 in Q4 2023.
LENZ Therapeutics (LENZ) has 5 years of Other Non-Current Liabilities data on file, last reported at $111000.0 in Q1 2024.
- Quarterly Other Non-Current Liabilities fell 87.26% year-over-year to $111000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $111000.0 (down 87.26% YoY) and the FY2023 annual result came in at $871000.0, down 91.95% from the prior year.
- Other Non-Current Liabilities fell to $111000.0 in Q1 2024 per LENZ's latest filing, from $871000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $10.8 million in Q4 2022 and bottomed at $64000.0 in Q2 2021.
- The 5-year median for Other Non-Current Liabilities is $593500.0 (2020), against an average of $1.9 million.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities surged 3676.56%; it then slumped 91.95% in 2023.
- Tracing LENZ's Other Non-Current Liabilities over 5 years: stood at $316000.0 in 2020, then plunged by 79.75% to $64000.0 in 2021, then jumped by 16804.69% to $10.8 million in 2022, then tumbled by 91.95% to $871000.0 in 2023, then sank by 87.26% to $111000.0 in 2024.
- Per Business Quant, the three latest LENZ Other Non-Current Liabilities figures stand at $111000.0 (Q1 2024), $871000.0 (Q4 2023), and $871000.0 (Q1 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 111,000.00 |
| Dec 31, 2023 | 871,000.00 |
| Mar 31, 2023 | 871,000.00 |
| Dec 31, 2022 | 10.82 Mn |
| Sep 30, 2022 | 2.42 Mn |
| Sep 30, 2021 | 64,000.00 |
| Jun 30, 2021 | 64,000.00 |
| Dec 31, 2020 | 316,000.00 |